CRISPR therapies are revolutionizing medicine, making up 70% of current gene-editing trials. To accelerate the clinical development of CRISPR cell and gene therapies, Synthego has launched its new, state-of-the-art manufacturing facility. This flyer provides an insight into our new manufacturing capacity for the production of GMP-grade CRISPR sgRNAs.

CRISPR therapies are the future of personalized medicine. As an industry leader, Synthego’s mission is to provide a range of the highest quality sgRNAs to researchers who are developing CRISPR cell and gene therapies. Our new GMP manufacturing facility allows for efficient, large-scale production of sgRNAs, accelerating clinical development timelines.

In this flyer, take an exclusive look at Synthego’s state-of-the-art manufacturing facility:

  • An overview of the factory and its production capacity
  • Details of the facility’s labs, manufacturing processes, and certifications
  • How Synthego can increase your chances of success during clinical development

Download the Next-Generation GMP Facility flyer today!